Adverse event reporting information can be found at the bottom of the page

WockAIR® Place in Therapy

You are here: / WockAIR® Place in Therapy

Now you can choose a single inhaler – WockAIR® 160/4.5 mcg – for patients at all steps of the GINA treatment pathway in AIR-only or MART regimens2.

ICS/formoterol is the preferred maintenance (controller) and reliever recommended by GINA for adults and adolescents over 12 years at all treatment steps1. ICS/formoterol combination inhaler therapy. is also recommended by NICE for AIR and MART in those aged 12 years and over.[3]

SABA reliever monotherapy is no longer recommended due to safety concerns 2

(GINA 2023 Global Strategy for Asthma Management and Prevention).

In addition NICE guidelines state:  ‘Do not prescribe short-acting beta2 agonists to people of any age with asthma without a concomitant prescription of an ICS.’[3]

WockAIR Package Shot
WockAIR Place in Therapy

Pharmacological Effects

WockAIR® contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used both as an anti-inflammatory reliever and as maintenance treatment of asthma.2

Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations.2

Formoterol is a selective β2 adrenoceptor agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose-dependent, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose.2

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

REFERENCES

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from ginasthma.org

2. WockAIR® Summary of Product Characteristics

3. NICE Guideline: Asthma: Diagnosis, monitoring and chronic asthma management 27 Nov 2024 Available at www.nice.org/guidance/ng245

ABBREVIATIONS

AIR-anti-inflammatory reliever; MART – Maintenance and Reliever Therapy; GINA-Global Initiative for Asthma; ICS- inhaled corticosteroid; SABA -short acting beta agonist

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR06/25 July 2025